HUMA

Over the past six months, Humacyte's stock has shown significant volatility and a general downward trend, though with some recent increases, with the share price at $0.59 as of September 18, 2026, representing a 68.52% decline over the past year. In May 2026, H.C. Wainwright reiterated a 'Buy' rating with a $3.00 price target, anticipating top-line interim data from the V012 Phase 3 trial in June 2026. Also in May 2026, Humacyte reported Q1 2026 earnings with an EPS of -$0.09, beating forecasts, but revenue of $500,000 was significantly below expectations, leading BTIG to lower its price target. In June 2026, the company announced positive interim Phase 3 data for its bioengineered blood vessel, hitting a primary endpoint. The stock reached its all-time low of $0.5261 on August 13, 2026. In September 2026, the FDA authorized an extension of the expiration dating period for Symvess from 18 months to 36 months, expected to aid hospital adoption. Humacyte is also scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference in September 2026, and the stock has shown a 5.99% increase in the past month.